AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24872728 — intervention group
Group type: EXPERIMENTAL
Intervention: Early follow-up by telephone consultations (4 and 14 days post-discharge) in addition to conventional treatment
Number of subjects: 116
Study 24872728 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment following discharge from hospital
Number of subjects: 116
Study 24874071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in A/J mice
Number of subjects: 4
Study 24874071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in smokers with and without COPD
Number of subjects: 4
Study 24874071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrolein exposure
Number of subjects: 4
Study 24874071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inflammation established
Number of subjects: 4
Study 24875132 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 monotherapy (40/60/80 mg bid for 21 days)
Number of subjects: 17
Study 24875132 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 40 mg bid plus paclitaxel 90 mg/m² (days 1, 8, 15 of 28-day cycle)
Number of subjects: 17
Study 24875132 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 monotherapy and combination therapy
Number of subjects: 17
Study 24875672 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-high isoflavone consumption (>1.48 mg/day, N = 65)
Number of subjects: 215
Study 24875672 — intervention group
Group type: EXPERIMENTAL
Intervention: High isoflavone consumption
Number of subjects: 215
Study 24875672 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy consumption
Number of subjects: 215
Study 24876081 — intervention group
Group type: EXPERIMENTAL
Intervention: Better collateral grade (American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology)
Number of subjects: 119
Study 24876081 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse collaterals
Number of subjects: 119
Study 24876081 — intervention group
Group type: EXPERIMENTAL
Intervention: Better collaterals
Number of subjects: 119
Study 24876081 — intervention group
Group type: EXPERIMENTAL
Intervention: Better collateral grade
Number of subjects: 119
Study 24876082 — intervention group
Group type: EXPERIMENTAL
Intervention: Trevo thrombectomy
Number of subjects: 228
Study 24876082 — intervention group
Group type: COMPARATOR
Intervention: Merci thrombectomy
Number of subjects: 228
Study 24876082 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 228
Study 24876082 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale score
Number of subjects: 228
Study 24876082 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom onset to endovascular treatment time
Number of subjects: 228
Study 24876082 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom onset to reperfusion time beyond 5 hours
Number of subjects: 228
Study 24876082 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage
Number of subjects: 228
Study 24876243 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities (ASPIRE) intervention
Number of subjects: 10256
Study 24876243 — intervention group
Group type: EXPERIMENTAL
Intervention: Community interventions (e.g., preparedness bracelets and stroke warning magnets)
Number of subjects: 10256
Study 24876243 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of emergency medical services and hospital processes for acute stroke care
Number of subjects: 10256
Study 24876244 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire FR thrombectomy
Number of subjects: 202
Study 24876244 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue-type plasminogen activator
Number of subjects: 202
Study 24876244 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance-based imaging at baseline
Number of subjects: 202
Study 24876244 — intervention group
Group type: COMPARATOR
Intervention: Extracranial carotid disease
Number of subjects: 202
Study 24876969 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Myopathy Assessment Tool (AMAT)
Number of subjects: 56
Study 24878054 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital adrenal hyperplasia (CAH) treatment
Number of subjects: 199
Study 24878054 — intervention group
Group type: COMPARATOR
Intervention: Non-salt-wasting classic CAH
Number of subjects: 199
Study 24878054 — intervention group
Group type: COMPARATOR
Intervention: Moderately affected genotype group B women
Number of subjects: 199
Study 24878054 — intervention group
Group type: COMPARATOR
Intervention: Late diagnosis of classic CAH (after 1 year)
Number of subjects: 199
Study 24878054 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid only treatment in women
Number of subjects: 199
Study 24878127 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 2209
Study 24878127 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 2209
Study 24878127 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 2209
Study 24878127 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 2209
Study 24878127 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI in diabetics
Number of subjects: 2209
Study 24878127 — intervention group
Group type: COMPARATOR
Intervention: CABG in diabetics
Number of subjects: 2209
Study 24878127 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI in patients with multivessel disease
Number of subjects: 2209
Study 24878127 — intervention group
Group type: COMPARATOR
Intervention: CABG in patients with multivessel disease
Number of subjects: 2209
Study 24878127 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI in ST elevation myocardial infarction
Number of subjects: 2209
Study 24878127 — intervention group
Group type: COMPARATOR
Intervention: CABG in ST elevation myocardial infarction
Number of subjects: 2209
Study 24878825 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the dorsal pallidum (globus pallidus, GP)
Number of subjects: 2
Study 24879333 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib ECT (50 mg BID for 7 days)
Number of subjects: 24
Study 24879333 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib ECT (doses ≥ 40 mg BID)
Number of subjects: 24
Study 24879333 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib ECT
Number of subjects: 24
Study 24879786 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study 24879786 — intervention group
Group type: COMPARATOR
Intervention: Previous 23-valent polysaccharide vaccine (PPSV23)
Number of subjects: 0
Study 24879788 — intervention group
Group type: EXPERIMENTAL
Intervention: 454-GSS
Number of subjects: 132
Study 24879788 — intervention group
Group type: EXPERIMENTAL
Intervention: 454-GSS < 3
Number of subjects: 132
Study 24879788 — intervention group
Group type: COMPARATOR
Intervention: Sanger-GSS < 3
Number of subjects: 132
Study 24879788 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous antiretrovirals received
Number of subjects: 132
Study 24879813 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation stopped in patients with persistently negative D-dimer (528 patients)
Number of subjects: 1010
Study 24879813 — intervention group
Group type: COMPARATOR
Intervention: Patients who resumed anticoagulation (373 patients)
Number of subjects: 1010
Study 24879813 — intervention group
Group type: COMPARATOR
Intervention: Patients who refused anticoagulation (109 patients)
Number of subjects: 1010
Study 24879827 — intervention group
Group type: EXPERIMENTAL
Intervention: Veo
Number of subjects: 27
Study 24879827 — intervention group
Group type: COMPARATOR
Intervention: FBP
Number of subjects: 27
Study 24879829 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief-H-Neg
Number of subjects: 5000
Study 24879829 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief-H-Pos
Number of subjects: 5000
Study 24879844 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT
Number of subjects: 439
Study 24879844 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 439
Study 24879844 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hsTnT and NT-proBNP
Number of subjects: 439
Study 24879844 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT addition
Number of subjects: 439
Study 24879844 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP addition
Number of subjects: 439
Study 24879844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both markers together
Number of subjects: 439
Study 24880136 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus salivarius PS2) administered for 21 days
Number of subjects: 0
Study 24880739 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in body mass index (BMI)
Number of subjects: 2593
Study 24880739 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in waist circumference (WC)
Number of subjects: 2593
Study 24880739 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in waist circumference-height ratio (WHtR)
Number of subjects: 2593
Study 24881994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs)
Number of subjects: 1250000
Study 24881994 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure
Number of subjects: 1250000
Study 24881994 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure of 90-114 mm Hg and diastolic blood pressure of 60-74 mm Hg
Number of subjects: 1250000
Study 24881994 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure
Number of subjects: 1250000
Study 24881994 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised diastolic blood pressure
Number of subjects: 1250000
Study 24881994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 1250000
Study 24881994 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable and unstable angina
Number of subjects: 1250000
Study 24881994 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure and stable angina
Number of subjects: 1250000
Study 24882673 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg orally daily
Number of subjects: 60
Study 24883065 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum levels of FGF21 in girls
Number of subjects: 179
Study 24883065 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum levels of FGF21 in boys
Number of subjects: 179
Study 24883065 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of baseline FGF21 levels with triglycerides
Number of subjects: 179
Study 24883065 — intervention group
Group type: COMPARATOR
Intervention: Correlation of baseline FGF21 levels with BMI, DXA-derived fat percentage, LDL, HDL, non-HDL cholesterol, leptin, and adiponectin
Number of subjects: 179
Study 24883065 — intervention group
Group type: COMPARATOR
Intervention: Correlation of baseline FGF21 levels with dynamic changes in glucose and insulin levels during OGTT
Number of subjects: 179
Study 24883207 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester elevated homocysteine levels
Number of subjects: 100
Study 24883378 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence Rate (RR) analysis
Number of subjects: 14
Study 24883378 — intervention group
Group type: COMPARATOR
Intervention: Spectral analysis
Number of subjects: 14
Study 24883378 — intervention group
Group type: COMPARATOR
Intervention: Bispectral analysis
Number of subjects: 14
Study 24883378 — intervention group
Group type: COMPARATOR
Intervention: Approximate entropy
Number of subjects: 14
Study 24883378 — intervention group
Group type: COMPARATOR
Intervention: Nonlinear energy operator (NLEO)
Number of subjects: 14
Study 24884405 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation (KT)
Number of subjects: 1000
Study 24884512 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (5 g/d of fish oil supplement containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid) for 6 weeks
Number of subjects: 210
Study 24884512 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 210
Study 24884681 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological examination, Glascow Coma Scale, and Modified Mini-Mental State Examination
Number of subjects: 55
Study 24884681 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial clinical presentation with coma
Number of subjects: 55
Study 24884681 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and gender factors
Number of subjects: 55
Study 24884681 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cranial nerve deficits at onset
Number of subjects: 55
Study 24884694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment of cardiovascular risk factors over 3 months, maintained for 2 years.
Number of subjects: 97
Study 24884708 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease management and monitoring
Number of subjects: 2450
Study 24884782 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release hydrocortisone
Number of subjects: 801
Study 24884782 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucocorticoid replacement therapy
Number of subjects: 801
Study 24884784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program delivered for 48 weeks with a 24-week post-intervention follow-up.
Number of subjects: 0
Study 24884976 — intervention group
Group type: EXPERIMENTAL
Intervention: Seva (E-Health integrated communication technology delivered via mobile phones)
Number of subjects: 0
Study 24885112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor metabolic progression index (TMPI) measured by serial FDG PET-CT
Number of subjects: 0
Study 24885112 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tumor FDG uptake
Number of subjects: 0
Study 24885112 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based apparent diffusion coefficient (ADC) and variation of vADC using voxel-based diffusion maps
Number of subjects: 0
Study 24885112 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 0
Study 24885112 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic and epigenetic factors
Number of subjects: 0
Study 24885137 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese men (BMI ≥30 kg/m2)
Number of subjects: 4131
Study 24885137 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight women (BMI 25-29.9 kg/m2)
Number of subjects: 4131
Study 24885137 — intervention group
Group type: COMPARATOR
Intervention: Normal weight subjects (BMI 18.5-24.9 kg/m2)
Number of subjects: 4131
Study 24885258 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted therapies
Number of subjects: 1000
Study 24885258 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 1000
Study 24885258 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization
Number of subjects: 1000
Study 24885258 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data abstraction
Number of subjects: 1000
Study 24885258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor tissue and blood sample collection
Number of subjects: 1000
Study 24885258 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinicopathological data
Number of subjects: 1000
Study 24885461 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-left sleeping position
Number of subjects: 1245
Study 24885461 — intervention group
Group type: COMPARATOR
Intervention: Control group (ongoing singleton pregnancies)
Number of subjects: 1245
Study 24885544 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement multi-faceted program including organizational, environmental, educational, human, and security approaches.
Number of subjects: 45260
Study 24885621 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic training (1-day)
Number of subjects: 96
Study 24885621 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced training (3-day)
Number of subjects: 96
Study 24885689 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) liquid cord cleansing
Number of subjects: 80
Study 24885689 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and health workers' practices regarding delivery and cord care
Number of subjects: 80
Study 24885689 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of sterilized equipment during delivery
Number of subjects: 80
Study 24885689 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of breastfeeding and feeding colostrum
Number of subjects: 80
Study 24885689 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping babies warm after birth and delaying the first bath
Number of subjects: 80
Study 24885755 — intervention group
Group type: EXPERIMENTAL
Intervention: IOERT with a median dose of 15 Gy, median electron energy of 6 MeV, median cone size of 9 cm
Number of subjects: 50
Study 24885755 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative EBRT with a median dose of 46 Gy after IOERT or 60 Gy without IOERT
Number of subjects: 50
Study 24885755 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative EBRT
Number of subjects: 50
Study 24885755 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy including IOERT and postoperative EBRT
Number of subjects: 50
Study 24885966 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 51
Study 24885966 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 51
Study 24886078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar absorption test in FD patients
Number of subjects: 19
Study 24886078 — intervention group
Group type: COMPARATOR
Intervention: Sugar absorption test in controls
Number of subjects: 19
Study 24886078 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of anxiety and depression in FD patients
Number of subjects: 19
Study 24886078 — intervention group
Group type: COMPARATOR
Intervention: Assessment of anxiety and depression in controls
Number of subjects: 19
Study 24886078 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell and eosinophil density assessment in FD patients
Number of subjects: 19
Study 24886128 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention group
Number of subjects: 30
Study 24886128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24886192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary ascorbic acid intake (100 mg/day higher)
Number of subjects: 7569
Study 24886192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary ascorbic acid intake
Number of subjects: 7569
Study 24886192 — intervention group
Group type: EXPERIMENTAL
Intervention: High content of dietary ascorbic acid
Number of subjects: 7569
Study 24886233 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of biomarkers (MFAP4 and SP-D) for predicting COPD trajectory
Number of subjects: 350
Study 24886233 — intervention group
Group type: EXPERIMENTAL
Intervention: Data capture system from GPs' electronic patient records
Number of subjects: 350
Study 24886233 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly consultations and follow-up using data capture system
Number of subjects: 350
Study 24886374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner sexual aggression
Number of subjects: 745
Study 24886374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner physical violence and sexual aggression
Number of subjects: 745
Study 24886374 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically forced sex
Number of subjects: 745
Study 24886374 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-physical coercive tactics
Number of subjects: 745
Study 24886512 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 18
Study 24886512 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus treatment with positive expression of phospho-mTOR
Number of subjects: 18
Study 24886512 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus treatment with positive expression of phospho-S6RP
Number of subjects: 18
Study 24886512 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus treatment with negative expression of phospho-4EBP1 and phospho-AKT
Number of subjects: 18
Study 24886572 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-optimized curcumin (Flexofytol®) 2x3 caps/day for 3 months
Number of subjects: 22
Study 24886772 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 19
Study 24887445 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted tailored intervention
Number of subjects: 0
Study 24887615 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home (PCMH)
Number of subjects: 143489
Study 24887615 — intervention group
Group type: COMPARATOR
Intervention: Paper Medical Records
Number of subjects: 143489
Study 24887615 — intervention group
Group type: COMPARATOR
Intervention: Electronic Health Records (EHR) without PCMH
Number of subjects: 143489
Study 24888813 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA peptide vaccination with EphA2, IL-13Rα2, and survivin peptides emulsified in Montanide-ISA-51, administered subcutaneously every 3 weeks for eight courses, followed by booster vaccinations every 6 weeks.
Number of subjects: 26
Study 24888813 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA peptide vaccination
Number of subjects: 26
Study 24889179 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) at 250 mg/day for 24 weeks
Number of subjects: 19
Study 24889281 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated blood glucose values
Number of subjects: 297
Study 24889281 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose testing
Number of subjects: 297
Study 24889836 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 1635
Study 24889836 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 1635
Study 24889836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 1635
Study 24889836 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin Questionnaire
Number of subjects: 1635